Scarica l'app Stockscreener
4.01
0.25%
-0.010
Dopo l'orario di chiusura:
3.99
-0.02
-0.50%
Cervomed Inc Borsa (CRVO) Ultime notizie
Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus
CervoMed to Participate in Upcoming Investor Conferences - The Manila Times
Biotech chasing age-related brain drugs makes March investor pitch - Stock Titan
CervoMed sets 50mg dose for phase 3 dementia trial By Investing.com - Investing.com Canada
CervoMed Finalizes Formulation and Dosing Regimen for Phase 3 Trial in Dementia with Lewy Bodies - geneonline.com
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com Australia
CervoMed Advances Neflamapimod With Phase 1 Completion - TipRanks
CervoMed (CRVO) Analyst Rating Update: Buy Rating Maintained by D. Boral Capital | CRVO Stock News - GuruFocus
Phase 3 neflamapimod dose set at 50 mg, CervoMed Inc. asserts - Traders Union
CervoMed Inc. Announces Successful Phase 1 Study of Stable Crystal Form of Neflamapimod and Planned Phase 3 Trial Dosing Regimen for Dementia with Lewy Bodies - Quiver Quantitative
CervoMed picks 50mg dose for dementia drug after Phase 1 study - Stock Titan
Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Guidance Update: Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
How do insiders feel about CervoMed Inc2025 Institutional Moves & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Stock Analysis: What is CervoMed Incs revenue forecastJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn
CRVOCervoMed Latest Stock News & Market Updates - Stock Titan
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target - TipRanks
CervoMed’s neflamapimod selected for UK ALS trial platform By Investing.com - Investing.com Canada
CervoMed’s Neflamapimod Added to U.K. ALS Platform - TipRanks
CervoMed's neflamapimod selected for UK EXPERTS-ALS; first ALS dosing expected by end of 2026 - TradingView
Neflamapimod joins UK EXPERTS-ALS platform for ALS at CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Analyst Rating Maintained as "Buy" by D. Boral C - GuruFocus
CervoMed’s neflamapimod selected for UK ALS trial platform - Investing.com
CervoMed's Neflamapimod Chosen For UK EXPERTS-ALS Platform - Nasdaq
CervoMed (CRVO) Drug Candidate Joins EXPERTS-ALS Platform - GuruFocus
CervoMed's neflamapimod elected for inclusion in UK Experts-ALS Platform - marketscreener.com
CervoMed Inc. Announces Inclusion of Neflamapimod in EXPERTS-ALS Platform for ALS Trial - Quiver Quantitative
Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform - TradingView
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis - Yahoo Finance
Will CervoMed Inc. benefit from seasonalityJuly 2025 Setups & Smart Investment Allocation Tips - mfd.ru
Aug Summary: Is CervoMed Inc stock a good pick for beginnersWeekly Profit Recap & High Return Stock Watch Alerts - baoquankhu1.vn
Should You Buy CervoMed Inc (CRVO) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Form 4: Blackburn Kelly reports acquisition/exercise transactions in CRVO - Stock Titan
Is CervoMed Inc. stock a good pick for beginnersJuly 2025 Closing Moves & Growth Focused Stock Reports - mfd.ru
What’s the analyst consensus on CervoMed Inc.2025 Support & Resistance & High Accuracy Investment Signals - mfd.ru
CervoMed (NASDAQ:CRVO) Upgraded at Brookline Capital Management - Defense World
Winners Losers: Is ALCY affected by consumer sentiment2025 Macro Impact & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Market Outlook: Is CervoMed Inc currently under institutional pressure2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Nasdaq Moves: Whats ACRES Commercial Realty Corps historical returnJuly 2025 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Inc targets breakthrough in Lewy body dementia treatment - Traders Union
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Is CervoMed Inc stock good for income investorsWeekly Trade Summary & Daily Stock Trend Reports - baoquankhu1.vn
Geopolitics Watch: Is CervoMed Inc stock a good pick for beginnersTrade Volume Report & Verified Chart Pattern Signals - baoquankhu1.vn
Market Overview: Does Coupang Inc have pricing powerChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
CervoMed (NASDAQ:CRVO) Upgraded at Zacks Research - Defense World
Growth Review: Can VSTEW sustain its profitabilityTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Ideas Watch: Is CervoMed Inc DP8 stock overpriced at current multiplesTrade Analysis Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
Will CervoMed Inc. stock see insider buying2025 Breakouts & Breakdowns & Smart Swing Trading Techniques - Улправда
Will CervoMed Inc. stock deliver consistent dividends2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Is CervoMed Inc. (DP8) stock overpriced at current multiples2025 Year in Review & Daily Market Momentum Tracking - Улправда
CervoMed Releases Updated Investor Presentation and Business Overview - TipRanks
Is CervoMed Inc. stock a dividend growth opportunityWeekly Trade Review & Long-Term Growth Stock Strategies - Улправда
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):